Dr. Louis M. Weiner, MD, is a nationally recognized medical oncologist specializing in gastrointestinal malignancies and immuno-oncology. He serves as Director of the Lombardi Comprehensive Cancer Center at Georgetown University and holds the Francis L. and Charlotte G. Gragnani Chair. Dr. Weiner earned his medical degree from Mount Sinai School of Medicine and completed residency training at the University of Vermont, followed by fellowship training in medical oncology at Tufts-New England Medical Center. He is board-certified in Internal Medicine and Medical Oncology and widely regarded for his leadership in translational cancer research.
Dr. Weiner’s research has focused on therapeutic monoclonal antibodies and the tumor microenvironment, with a particular emphasis on translating immune-based therapies into clinical practice. He has led multiple clinical trials in gastrointestinal and other cancers and has authored hundreds of peer-reviewed publications. His work has significantly advanced understanding of immune checkpoint therapies and antibody-based strategies.
In addition to his research leadership, Dr. Weiner has served on numerous national boards and committees, including the American Association for Cancer Research (AACR) and the National Cancer Institute. A dedicated mentor, he has trained many oncologists and researchers who now hold leadership positions in the field. Through his work in immunotherapy and his vision for comprehensive cancer care, Dr. Louis M. Weiner continues to shape the future of oncology.
Education
Medical School:
Mount Sinai School of Medicine
Residency:
Internship and Residency University of Vermont Medical Center Hospital
Fellowship:
Hematology and Oncology, Tufts University School of Medicine Boston
Board Certification:
American Board of Internal Medicine, American Board of Medical Oncology
Awards
- AACR Distinguished Public Service Award – 2019
Memberships and affiliations
- American Association for Cancer Research
- American Society of Clinical Oncology
- Founder – AACR Cancer Immunology Working Group
- Chair – NCI Board of Scientific Counselors for Clinical Sciences and Epidemiology
- NCI Clinical Trials Advisory Committee (CTAC)
- NIH CSR Advisory Panels
- Georgetown University Hospital
- MedStar Georgetown Cancer Institute
- Lombardi Comprehensive Cancer Center
Research and publications
- Phase II Trial of BXCL701 Plus Pembrolizumab in Second-Line Advanced Pancreatic Ductal Adenocarcinoma
Other medical oncologist listed alphabetically, never by payment.
Browse all doctors →Open trials for these cancers, with the eligibility rules written in plain language.
Search trials →